Autonomix Medical, Inc.

Autonomix Medical, Inc. is a development-stage medical device company that focuses on advancing technologies for sensing and treating disorders of the nervous system. The company's platform integrates high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, aiming for a "sense, treat, verify" approach to improve the precision and consistency of nerve-targeted therapies. Its technology is a catheter-based system that includes a proprietary microchip-enabled sensing architecture. This architecture is designed to detect low-amplitude neural signals from within the vascular system by placing signal amplification and digitization at or near the point of detection, which is intended to reduce signal degradation and improve neural activity detection compared to conventional systems. Autonomix Medical's development efforts are focused on two core components: diagnostic sensing and therapeutic RF ablation. Preclinical studies have shown the sensing technology can detect signals from specific nerve bundles before ablation and confirm signal termination after treatment. The company is currently refining its catheter design for human use in the United States. In parallel, an early clinical proof-of-concept study evaluated the safety and feasibility of transvascular nerve ablation using commercially available RF ablation technologies. After positive initial findings, an expansion study was initiated but enrollment was paused due to observed variability in early clinical outcomes, potentially related to differences in vascular access and anatomical targeting. The company is initially developing its technology for treating pain associated with pancreatic cancer.